Oslo, April 10 2025. Navamedic ASA (OSE ticker “NAVA”) has entered into an agreement in principle regarding the outstanding loans to Observe Medical ASA. The agreement reduces the loans by 50% with an adjustment to the payment plan as long as certain conditions are met, including the injection of new equity in Observe Medical ASA from other parties of at least 25MNOK, and that other creditors also reduces their debt at the same level. Navamedic will further have the possibility of receiving milestone payments up to 20MNOK based on Observe Medical ASA achieving certain sales levels of Sippi.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: lars.hjarrand@navamedic.com

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 the Norwegian Securities Trading Act.

This stock exchange announcement was published by Lars Hjarrand, CFO of the Company, on 10 April 2025 at 08.50 hours CET on behalf of the Company.

About Navamedic:

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people’s quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson’s disease, antibiotics and metabolism, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit Navamedic.com.